Promising new cocktail targets AIDS-Linked cancers

NCT ID NCT03220022

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This early-phase trial is testing whether adding the targeted drug ibrutinib to standard chemotherapy can safely treat HIV-positive patients with a type of lymphoma. The study involves 46 participants and aims to find the best dose and check for side effects. If it works, this combination could offer a new frontline option for this hard-to-treat group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ibrutinib (a targeted cancer drug) combined with chemotherapy (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin)
What this could lead to: If successful, this could lead to a more effective first-line treatment option for people with HIV-related lymphoma, potentially improving cancer control.
What could go wrong: This is an early phase 1 trial with only 46 participants, focused on safety and dosing. It is too small to prove effectiveness, and the combination may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma Lymphoma, AIDS-Related primary effusion lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

Boston Medical Center

Boston, Massachusetts, 02118, United States
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
John H Stroger Jr Hospital of Cook County

Chicago, Illinois, 60612, United States
Johns Hopkins University/Sidney Kimmel Cancer Center

Baltimore, Maryland, 21287, United States
Memorial Hospital West

Pembroke Pines, Florida, 33028, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Nassau

Uniondale, New York, 11553, United States
Montefiore Medical Center - Moses Campus

The Bronx, New York, 10467, United States
Mount Sinai Hospital

New York, New York, 10029, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
Pennsylvania Hospital

Philadelphia, Pennsylvania, 19107, United States
Siteman Cancer Center at Washington University

St Louis, Missouri, 63110, United States
UC San Diego Moores Cancer Center

La Jolla, California, 92093, United States
UCSF Medical Center-Parnassus

San Francisco, California, 94143, United States
UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, 27599, United States
University of Illinois College of Medicine - Chicago

Chicago, Illinois, 60612, United States
University of Miami Miller School of Medicine-Sylvester Cancer Center

Miami, Florida, 33136, United States
Virginia Mason Medical Center

Seattle, Washington, 98101, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.